Understanding why and how chemotherapy resistance occurs is a major step toward optimizing treatments for cancer. A team of scientists including Markus Seeliger, Ph.D., of the Stony Brook Cancer Center and Renaissance School of Medicine at Stony Brook University, believe they have found a new process through which drug resistance happens. They are using a computer simulation model that is helping them understand exactly how molecules interact with the cancer drug Imatinib (known as Gleevec) in the chemotherapy resistant process. Imatinib treats chronic myeloid leukemia (CML) highly effectively, yet many late stage patients experience drug resistance, which renders the drug minimally effective at that stage.
Click here for original story, Computer simulations of proteins help unravel why chemotherapy resistance occurs
Source: Phys.org